Corrado Barbui,Giovanni Ostuzzi
Corrado Barbui
Magdalena Sanz Cortes
Magdalena Sanz Cortes
Jonathan Thomas Evans,Jenna Shepherd
Jonathan Thomas Evans
The Lancet
The Lancet
Michael S Saag
Michael S Saag
Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial [0.03%]
从复杂的HIV方案切换到单片剂bictegravir-loncapavir（ARTISTRY-1）：一项随机、开放标签、III期临床试验
Chloe Orkin,Peter J Ruane,Malcolm Hedgcock et al.
Chloe Orkin et al.
Background: Single-tablet regimens (STRs) revolutionised HIV-1 treatment, improving adherence and clinical outcomes; however, many people cannot take these due to resistance, contraindications, or drug-drug interactions, ...
Fundamental PEPFAR reform risks a period of structural vulnerability in the HIV response [0.03%]
关于PEPFAR根本性改革可能导致艾滋病应对出现结构性脆弱时期的反思
Jirair Ratevosian,Chris Beyrer
Jirair Ratevosian
Pegah A M Seidi,Dilshad Jaff,Zamdar H Rasul Karim
Pegah A M Seidi
Mohammad Karamouzian,Stefan D Baral
Mohammad Karamouzian